222 related articles for article (PubMed ID: 21487042)
21. Nedd8-Activating Enzyme Is a Druggable Host Dependency Factor of Human and Mouse Cytomegalovirus.
Flores-Martínez YA; Le-Trilling VTK; Trilling M
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452475
[TBL] [Abstract][Full Text] [Related]
22. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer.
Soucy TA; Smith PG; Milhollen MA; Berger AJ; Gavin JM; Adhikari S; Brownell JE; Burke KE; Cardin DP; Critchley S; Cullis CA; Doucette A; Garnsey JJ; Gaulin JL; Gershman RE; Lublinsky AR; McDonald A; Mizutani H; Narayanan U; Olhava EJ; Peluso S; Rezaei M; Sintchak MD; Talreja T; Thomas MP; Traore T; Vyskocil S; Weatherhead GS; Yu J; Zhang J; Dick LR; Claiborne CF; Rolfe M; Bolen JB; Langston SP
Nature; 2009 Apr; 458(7239):732-6. PubMed ID: 19360080
[TBL] [Abstract][Full Text] [Related]
23. Human geminin promotes pre-RC formation and DNA replication by stabilizing CDT1 in mitosis.
Ballabeni A; Melixetian M; Zamponi R; Masiero L; Marinoni F; Helin K
EMBO J; 2004 Aug; 23(15):3122-32. PubMed ID: 15257290
[TBL] [Abstract][Full Text] [Related]
24. Suppression of glioblastoma by targeting the overactivated protein neddylation pathway.
Hua W; Li C; Yang Z; Li L; Jiang Y; Yu G; Zhu W; Liu Z; Duan S; Chu Y; Yang M; Zhang Y; Mao Y; Jia L
Neuro Oncol; 2015 Oct; 17(10):1333-43. PubMed ID: 25904638
[TBL] [Abstract][Full Text] [Related]
25. MLN4924 therapy as a novel approach in cancer treatment modalities.
Oladghaffari M; Islamian JP; Baradaran B; Monfared AS
J Chemother; 2016 Apr; 28(2):74-82. PubMed ID: 26292710
[TBL] [Abstract][Full Text] [Related]
26. Targeting neddylation induces DNA damage and checkpoint activation and sensitizes chronic lymphocytic leukemia B cells to alkylating agents.
Paiva C; Godbersen JC; Berger A; Brown JR; Danilov AV
Cell Death Dis; 2015 Jul; 6(7):e1807. PubMed ID: 26158513
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia.
Swords RT; Kelly KR; Smith PG; Garnsey JJ; Mahalingam D; Medina E; Oberheu K; Padmanabhan S; O'Dwyer M; Nawrocki ST; Giles FJ; Carew JS
Blood; 2010 May; 115(18):3796-800. PubMed ID: 20203261
[TBL] [Abstract][Full Text] [Related]
28. Radiosensitization of Human Colorectal Cancer Cells by MLN4924: An Inhibitor of NEDD8-Activating Enzyme.
Wan J; Zhu J; Li G; Zhang Z
Technol Cancer Res Treat; 2016 Aug; 15(4):527-34. PubMed ID: 26082455
[TBL] [Abstract][Full Text] [Related]
29. Targeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924).
Wong KM; Micel LN; Selby HM; Tan AC; Pitts TM; Bagby SM; Spreafico A; Klauck PJ; Blakemore SJ; Smith PF; McDonald A; Berger A; Tentler JJ; Eckhardt SG
Invest New Drugs; 2017 Feb; 35(1):11-25. PubMed ID: 27783255
[TBL] [Abstract][Full Text] [Related]
30. A deneddylase encoded by Epstein-Barr virus promotes viral DNA replication by regulating the activity of cullin-RING ligases.
Gastaldello S; Hildebrand S; Faridani O; Callegari S; Palmkvist M; Di Guglielmo C; Masucci MG
Nat Cell Biol; 2010 Apr; 12(4):351-61. PubMed ID: 20190741
[TBL] [Abstract][Full Text] [Related]
31. Identification and application of NEDD8 E1 inhibitors.
Bruzzese FJ; Milhollen MA; Gavin JM; Josephine HR; Brownell JE
Methods Mol Biol; 2012; 832():577-88. PubMed ID: 22350913
[TBL] [Abstract][Full Text] [Related]
32. Nedd8 on cullin: building an expressway to protein destruction.
Pan ZQ; Kentsis A; Dias DC; Yamoah K; Wu K
Oncogene; 2004 Mar; 23(11):1985-97. PubMed ID: 15021886
[TBL] [Abstract][Full Text] [Related]
33. Mutations in UBA3 confer resistance to the NEDD8-activating enzyme inhibitor MLN4924 in human leukemic cells.
Xu GW; Toth JI; da Silva SR; Paiva SL; Lukkarila JL; Hurren R; Maclean N; Sukhai MA; Bhattacharjee RN; Goard CA; Medeiros B; Gunning PT; Dhe-Paganon S; Petroski MD; Schimmer AD
PLoS One; 2014; 9(4):e93530. PubMed ID: 24691136
[TBL] [Abstract][Full Text] [Related]
34. Broad and potent antiviral activity of the NAE inhibitor MLN4924.
Le-Trilling VT; Megger DA; Katschinski B; Landsberg CD; Rückborn MU; Tao S; Krawczyk A; Bayer W; Drexler I; Tenbusch M; Sitek B; Trilling M
Sci Rep; 2016 Feb; 6():19977. PubMed ID: 26829401
[TBL] [Abstract][Full Text] [Related]
35. MLN4924 (Pevonedistat), a protein neddylation inhibitor, suppresses proliferation and migration of human clear cell renal cell carcinoma.
Tong S; Si Y; Yu H; Zhang L; Xie P; Jiang W
Sci Rep; 2017 Jul; 7(1):5599. PubMed ID: 28717191
[TBL] [Abstract][Full Text] [Related]
36. Quantifiable analysis of cellular pathway inhibition of a Nedd8-activating enzyme inhibitor, MLN4924, using AlphaScreen.
Yan ZH; Burkhardt A; Loke HK; Chen J; Xu Q; Brauer P; Ma J; Lin Y; Garcia K; Dick LR; Bembenek ME
Anal Biochem; 2013 Aug; 439(2):109-15. PubMed ID: 23624319
[TBL] [Abstract][Full Text] [Related]
37. The NEDD8-activating enzyme inhibitor MLN4924 disrupts nucleotide metabolism and augments the efficacy of cytarabine.
Nawrocki ST; Kelly KR; Smith PG; Keaton M; Carraway H; Sekeres MA; Maciejewski JP; Carew JS
Clin Cancer Res; 2015 Jan; 21(2):439-47. PubMed ID: 25388161
[TBL] [Abstract][Full Text] [Related]
38. SOMCL-19-133, a novel, selective, and orally available inhibitor of NEDD8-activating enzyme (NAE) for cancer therapy.
Zhou LN; Xiong C; Cheng YJ; Song SS; Bao XB; Huan XJ; Wang TY; Zhang A; Miao ZH; He JX
Neoplasia; 2022 Oct; 32():100823. PubMed ID: 35907292
[TBL] [Abstract][Full Text] [Related]
39. Characterization of MRFAP1 turnover and interactions downstream of the NEDD8 pathway.
Larance M; Kirkwood KJ; Xirodimas DP; Lundberg E; Uhlen M; Lamond AI
Mol Cell Proteomics; 2012 Mar; 11(3):M111.014407. PubMed ID: 22038470
[TBL] [Abstract][Full Text] [Related]
40. Redundant control of rereplication in fission yeast.
Gopalakrishnan V; Simancek P; Houchens C; Snaith HA; Frattini MG; Sazer S; Kelly TJ
Proc Natl Acad Sci U S A; 2001 Nov; 98(23):13114-9. PubMed ID: 11606752
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
